Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

13.16 +1.90 (+16.87%)
Official Closing Price Updated: 7:00 PM EDT, Apr 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 134,324,546
Open 13.22
Bid (Size) 13.14 (100)
Ask (Size) 13.17 (10,700)
Prev. Close 11.26
Today's Range 13.15 - 13.24
52wk Range 5.690 - 13.24
Shares Outstanding 259,965,579
Dividend Yield 0.61%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Halper Sadeh LLC is Investigating Whether OGN, XOMA, RMAX, SLNO are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal ↗
Today, April 27, 2026, a jumbo all-cash buyout and merger-arb dynamics put Organon in focus. 
Via The Motley Fool
Topics Stocks

Performance

YTD
+81.8%
+81.8%
1 Month
+130.9%
+130.9%
3 Month
+44.6%
+44.6%
6 Month
+86.4%
+86.4%
1 Year
+3.5%
+3.5%

More News

Read More
Monday's session: most active stocks ↗
Via Chartmill
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
OGN Stock Alert: Halper Sadeh LLC is Investigating Whether Organon & Co. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Sun Pharma signs Definitive Agreement to Acquire Organon
From Organon & Co.
Via Business Wire
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
From Organon & Co.
Via Business Wire
News headline image
3 Reasons to Avoid OGN and 1 Stock to Buy Instead
Via StockStory
Topics Stocks
News headline image
Traders are paying attention to the gapping stocks in Friday's session. ↗
Via Chartmill
Topics Artificial Intelligence
News headline image
Discover the top movers in Friday's pre-market session. ↗
Via Chartmill
News headline image
Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know
Via StockStory
Topics Government Stocks
News headline image
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age
From Organon & Co.
Via Business Wire
News headline image
3 Cash-Producing Stocks We’re Skeptical Of
Via StockStory
Topics Fraud
News headline image
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? ↗
Via The Motley Fool
News headline image
3 Value Stocks We Approach with Caution
Via StockStory
News headline image
1 Stock Under $10 to Own for Decades and 2 That Underwhelm
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks We Approach with Caution
Via StockStory
News headline image
3 Small-Cap Stocks We Approach with Caution
Via StockStory
News headline image
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
From Organon & Co.
Via Business Wire
News headline image
The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy
Via Finterra
Topics Economy
News headline image
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
From Organon & Co.
Via Business Wire
News headline image
5 Revealing Analyst Questions From Organon’s Q4 Earnings Call
Via StockStory
Topics Earnings
News headline image
Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know
Via StockStory
Topics Economy

Frequently Asked Questions

Is Organon & Co. Common Stock publicly traded?
Yes, Organon & Co. Common Stock is publicly traded.
What exchange does Organon & Co. Common Stock trade on?
Organon & Co. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Organon & Co. Common Stock?
The ticker symbol for Organon & Co. Common Stock is OGN on the New York Stock Exchange
What is the current price of Organon & Co. Common Stock?
The current price of Organon & Co. Common Stock is 13.16
When was Organon & Co. Common Stock last traded?
The last trade of Organon & Co. Common Stock was at 04/27/26 07:00 PM ET
What is the market capitalization of Organon & Co. Common Stock?
The market capitalization of Organon & Co. Common Stock is 3.42B
How many shares of Organon & Co. Common Stock are outstanding?
Organon & Co. Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.